Lead Sponsor

AbbVie

Age

16 - 80 years

Sex

ALL

Healthy Volunteers

No

•Male or female aged \>=18 to \<= 80 years, or minimum age of adult consent according to local regulations, at the Baseline Visit. Where locally permissible, participants 16 to \< 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit.
•Diagnosis of CD for at least 3 months prior to Baseline.
•Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic Score for Crohn's Disease (SES-CD).
•Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD.
•If female, participant must meet the contraception recommendations.

•Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.
•Participants with unstable doses of concomitant Crohn's disease therapy.
•Receipt of Crohn's disease approved biologic agents (infliximab, adalimumab, certolizumab, vedolizumab, natalizumab within 8 weeks prior to Baseline or ustekinumab within 12 weeks prior to Baseline), or any investigational biologic or other agent or procedure within 35 days or 5 half-lives prior to Baseline, whichever is longer.
•Prior exposure to p19 inhibitors (e.g., risankizumab).
•Complications of Crohn's disease.
•Having an ostomy or ileoanal pouch.
•Known active Coronavirus Disease 2019 (COVID-19) infection.

Related studies

NCT07184931 · Crohn's Disease

NCT06100289 · Ulcerative Colitis, Crohn's Disease

NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more

NCT06180382 · Crohn's Disease

NCT07545317 · Crohn's Disease

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease